Efficacy of an intravenous low-molecular-weight dermatan sulphate (Desmin) in patients with acute proximal deep venous thrombosis and silent pulmonary embolism. A pilot study

Journal of International Medical Research

Volumn 25, Issue 2, 1997, Pages 98-107

  Venosi, S ^a   Zamboni, V ^b   Irace, L ^a   Stumpo, R ^a   Massa, R ^c   Palazzint, E ^b   Benedetti Valentini, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Alfa Wassermann SpA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antithrombotics; Deep vein thrombosis; Desmin; Low molecular weight dermatan sulphate; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT; DERMATAN SULFATE; DESMIN; THROMBOPLASTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; LUNG SCINTISCANNING; MALE; REPERFUSION; SCINTIPHLEBOGRAPHY;

EID: 0030995131     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059702500207     Document Type: Article

References (37)

1. Salzman EW, Deykin D, Shapiro RM, et al: Management of heparin therapy: controlled prospective trial. N Engl J Med 1975; 292: 1046 - 1050.
2. Moser KM: Venous thromboembolism: state of the art. Am Rev Respir Dis 1990; 141: 235 - 249.
3. Hull RD: Anticoagulant treatment. Int Angiol 1995; 14: 32 - 44.
4. Hirsh J, Dalen JE, Deykin D, et al: Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1992; 102 (Suppl 4): 337S - 351S.
5. Hull RB, Raskob GE, Rosenbloom D, et al: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260 - 1264.
6. Johnson BF, Manzo RA, Bergelin RO, et al: Relationship between changes in the deep venous system and the development of the post-thrombotic syndrome after an acute episode of lower limb deep venous thrombosis. A one- to six-year follow-up. J Vasc Surg 1994; 21: 307 - 313.
7. Prandoni P, Villalta S, Polistena P, et al: Symptomatic deep-vein thrombosis and post-thrombotic syndrome. Haematologica 1995; 80 (Suppl 2): 42 - 48.
8. Hull RB, Raskob GE, Hirsh J, et al: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109 - 1114.
9. Hommes DA, Bura A, Mazzolai L, et al: Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992; 116: 279 - 284.
10. Warkentin TE, Levin MN, Hirsh J, et al: Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330 - 1335.
11. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995; 332: 1374 - 1376.
12. Prandoni P, Lensing AW, Buller HR, et al: Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441 - 445.
13. Simonneau G, Charbonnier B, Decousus H, et al: Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153: 1541 - 1546.
14. Hull RD, Raskob GE, Pineo GF, et al: Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975 - 982.
15. Weinmann EE, Salzman EW: Deep vein thrombosis. N Engl J Med 1994; 331: 1630 - 1641.
16. Volteas SK, Kalodiki E, Nicolaides AN: Low molecular weight heparins in the initial treatment of deep vein thrombosis. Int Angiol 1996; 15: 67 - 74.
17. Green D, Hirsh J, Heit J, et al: Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1995; 461: 89 - 109.
18. Lensing AWA, Prins MH, Davidson BL, et al: Treatment of deep venous thrombosis with low molecular weight heparins. Arch Intern Med 1995; 155: 601 - 607.
19. Siragusa S, Cosmi B, Piovella F, et al: Low molecular weight heparins and unfractioned heparin in the treatment of acute deep vein thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269 - 277.
20. Mascellani G, Bianchini P. European Patent 1990; No. 0221977. USA Patent No. 4973580.
21. Tamagnone G, Barbanti M: Desmin 370. Drugs Fut 1994; 19: 638 - 640.
22. Barbanti M, Calanni F, Babbini M, et al: Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Thromb Res 1993; 71: 417 - 422.
23. Barbanti M, Calanni F, Milani MR, et al: Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis. Evidence for an anticoagulant-independent mechanism. Thromb Haemost 1993; 69: 147 - 151.
24. Barbanti M, Calanni F, Marchi E, et al: Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in experimental venous thrombosis in rat: comparison with t-PA and u-PA (abstract). Thromb Haemost 1993; 69: 860.
25. Colucci M, Triggiani R, Cavallo LG, et al: Therapeutic effect of a LMW-dermatan sulfate in experimental venous thrombosis. Comparison with hirudin and heparin. Fibrinolysis 1992; 6: 136 - 140.
26. Barbanti M, Calanni F, Marchi E, et al: Desmin 370, a low molecular weight dermatan sulphate, reduces the weight of preformed thrombi in rats made afibrinogenemic by Ancrod. Thromb Haemost 1995; 73(2): 287 - 290.
27. Dettori AG, Galli G, Manotti C, et al: Pharmacological activity of a low molecular weight dermatan sulphate (Desmin) in healthy volunteers. Sem Thromb Hemost 1994; 20: 259 - 265.
28. Dettori AG, Manotti C, Palazzini E, et al: Pharmacology of Desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg). Thromb Res 1995; 79: 249 - 260.
29. Legnani C, Palareti G, Biagi R, et al: Acute and chronic clotting and fibrinolytic effect of a new low molecular weight dermatan sulphate (Desmin 370) in healthy subjects. Eur J Clin Pharm 1994; 47: 247 - 252.
30. Cucinotta D, Manopulo R, Galati M, et al: Pharmacodynamics of a new low-molecular-weight dermatan sulfate after a single subcutaneous injection in elderly patients with chronic venous disorders: a Phase 1 trial. Curr Ther Res 1994; 55: 1492 - 1500.
31. Traini AM, Cervi V, Melandri G, et al: Pharmacodynamic characteristics of a low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction. J Int Med Res 1994; 22: 323 - 331.
32. Anderson FA, Wheeler HB, Goldberg RJ, et al: A population-based perspective of the hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 993 - 998.
33. Nielsen HK, Husted SE, et al: Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med 1994; 235: 457 - 461.
34. Moser KM, Fedullo PF, Littlejohn JK, et al: Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994; 271: 223 - 225.
35. Huisman MV, Büller HR, ten Gate JW, et al: Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1995; 95: 498 - 502.
36. Charbonnier B, Pacouret G: Place des héparines de bas poids moléculaire pour traiter les embolies pulmonaires non massives. Presse Med 1996; 39: 1821 - 1825.
37. Urokinase Pulmonary Embolism Trial (UPET). A national cooperative study. Circulation 1973; 47(Suppl II): 1 - 108.